Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
quadrivalent influenza modRNA vaccine (PF-07252220) / Pfizer, BioNTech
NCT05540522: A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older	Completed	3	46169	US, RoW	Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine	Pfizer	Influenza, Human	03/24	03/24
NCT05052697: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza	Completed	1/2	1158	US	mIRV, bIRV AB, qIRV, QIV, bIRV AA, bIRV BB	Pfizer	Influenza, Human	01/23	01/23
NCT05596734: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza	Completed	1/2	1019	US	bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV, bIRV, tIRV	BioNTech SE, Pfizer	Influenza, Human, COVID-19	12/23	12/23
NCT05788237: A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults	Completed	1	508	RoW	RSVpreF+qIRV, qIRV, PF-07252220, RSVpreF, PF-06928316, Placebo, RSVpreF + qIRV 1.0 mL formulation, PF-07941314, RSVpreF + qIRV 0.5 mL formulation	Pfizer	Healthy	09/23	09/23